FourThought Financial Partners LLC Invests $559,000 in Danaher Co. (NYSE:DHR)

FourThought Financial Partners LLC purchased a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,433 shares of the conglomerate’s stock, valued at approximately $559,000.

A number of other institutional investors have also recently made changes to their positions in DHR. Heck Capital Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth $27,000. Decker Retirement Planning Inc. bought a new position in shares of Danaher in the 4th quarter worth $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher in the 4th quarter worth $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher in the 4th quarter worth $31,000. Finally, Pineridge Advisors LLC grew its holdings in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Friday, December 13th. The Goldman Sachs Group set a $250.00 target price on shares of Danaher in a report on Wednesday, January 15th. Barclays reduced their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Trading Down 0.2 %

NYSE:DHR opened at $210.65 on Wednesday. The company has a 50-day moving average price of $225.79 and a 200-day moving average price of $246.04. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $150.56 billion, a price-to-earnings ratio of 39.90, a P/E/G ratio of 2.66 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the business posted $2.09 earnings per share. Equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.